|MDACC Study No:||2012-1106(2011-0554SOLIDTUM) (clinicaltrials.gov NCT No: NCT01461538)|
|Title:||A phase 2, open-label study of brentuximab vedotin in patients with CD30-positive nonlymphomatous malignancies|
|Principal Investigator:||Jorge Cortes|
|Treatment Agent:||Brentuximab Vedotin|
|Study Description:||The goal of this clinical research study is to learn if Adcetris™ (brentuximab |
vedotin) can help to control advanced or metastatic leukemia that has the CD30
marker. The safety of this drug will also be studied.
Brentuximab vedotin is designed to stop tumor growth in cancer that has the
CD30 tumor marker.